Reducing Effect of Cannabidiol on Alcohol Self-Administration in Sardinian Alcohol-Preferring Rats

被引:14
作者
Maccioni, Paola [1 ]
Bratzu, Jessica [1 ]
Carai, Mauro A. M. [2 ]
Colombo, Giancarlo [1 ]
Gessa, Gian Luigi [1 ]
机构
[1] Natl Res Council Italy, Neurosci Inst, Sect Cagliari, SS 554,Km 4,500, I-09042 Monserrato, Italy
[2] Cagliari Pharmacol Res Srl, Cagliari, Italy
关键词
alcohol self-administration; cannabidiol; chocolate self-administration; endocannabinoid system; Sardinian alcohol-preferring rats; ANIMAL-MODELS; ALLOSTERIC MODULATOR; CB2; RECEPTOR; CONSUMPTION; MEDICATIONS; ANTAGONIST; FOOD;
D O I
10.1089/can.2020.0132
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Cannabidiol (CBD) is a major cannabinoid extracted from Cannabis sativa with no abuse potential. Data from recent rodent studies suggest that amelioration of alcohol-motivated behaviors may be one of the numerous pharmacological effects of CBD. This study was designed to contribute to this research, assessing the effect of CBD on operant oral alcohol self-administration in selectively bred Sardinian alcohol-preferring (sP) rats, a validated animal model of excessive alcohol consumption. In addition, this study investigated the effect of CBD on operant self-administration of a highly palatable chocolate solution in Wistar rats. Materials and Methods: Male sP rats were trained to lever respond for alcohol (15% v/v) under the fixed ratio 4 (FR4) schedule of reinforcement. Once lever responding had stabilized, rats were exposed to test sessions under the FR4 and progressive ratio (PR) schedules of reinforcement. Test sessions were preceded by acute treatment with CBD (0, 6.25, 12.5, and 25 mg/kg or 0, 25, 50, and 100 mg/kg, i.p.; each dose range was tested in an independent experiment). Male Wistar rats were trained to lever respond for a chocolate solution (5% w/v chocolate powder) under the FR10 schedule of reinforcement. Once lever responding had stabilized, rats were exposed to test sessions under the same schedule. Test sessions were preceded by acute treatment with CBD (0, 6.25, 12.5, and 25 mg/kg or 0, 25, 50, and 100 mg/kg, i.p., in two independent experiments). Results: Under the FR schedule, treatment with doses of CBD >= 12.5 mg/kg markedly reduced lever responding for alcohol and amount of self-administered alcohol. Under the PR schedule, treatment with CBD produced a slight tendency toward a decrease in lever responding and breakpoint for alcohol. Finally, no dose of CBD affected lever responding for the chocolate solution and amount of self-administered chocolate solution. Discussion: These results extend previous data on CBD ability to affect alcohol-motivated behaviors to an animal model of genetically-determined proclivity to high alcohol consumption. Because of the predictive validity of sP rats, these results may be of relevance in view of possible future studies testing CBD in patients affected by alcohol use disorder.
引用
收藏
页码:161 / 169
页数:9
相关论文
共 45 条
[1]   Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test [J].
Almeida, Valeria ;
Levin, Raquel ;
Peres, Fernanda Fiel ;
Niigaki, Suzy T. ;
Calzavara, Mariana B. ;
Zuardi, Antonio W. ;
Hallak, Jaime E. ;
Crippa, Jose A. ;
Abilio, Vanessa C. .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2013, 41 :30-35
[2]   Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol [J].
Alves, Patricia ;
Amaral, Cristina ;
Teixeira, Natercia ;
Correia-da-Silva, Georgina .
PHARMACOLOGICAL RESEARCH, 2020, 157
[3]   Endocannabinoid System and Alcohol Abuse Disorders [J].
Basavarajappa, Balapal S. .
RECENT ADVANCES IN CANNABINOID PHYSIOLOGY AND PATHOLOGY, 2019, 1162 :89-127
[4]   Rat animal models for screening medications to treat alcohol use disorders [J].
Bell, Richard L. ;
Hauser, Sheketha R. ;
Liang, Tiebing ;
Sari, Youssef ;
Maldonado-Devincci, Antoniette ;
Rodd, Zachary A. .
NEUROPHARMACOLOGY, 2017, 122 :201-243
[5]   Animal models for medications development targeting alcohol abuse using selectively bred rat lines: Neurobiological and pharmacological validity [J].
Bell, Richard L. ;
Sable, Helen J. K. ;
Colombo, Giancarlo ;
Hyytia, Petri ;
Rodd, Zachary A. ;
Lumeng, Lawrence .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2012, 103 (01) :119-155
[6]   Cannabidiol inhibits sucrose self-administration by CB1 and CB2 receptor mechanisms in rodents [J].
Bi, Guo-Hua ;
Galaj, Ewa ;
He, Yi ;
Xi, Zheng-Xiong .
ADDICTION BIOLOGY, 2020, 25 (04)
[7]   Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide [J].
Bisogno, T ;
Hanus, L ;
De Petrocellis, L ;
Tchilibon, S ;
Ponde, DE ;
Brandi, I ;
Moriello, AS ;
Davis, JB ;
Mechoulam, R ;
Di Marzo, V .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 134 (04) :845-852
[8]   Cannabidiol as a Potential Treatment for Anxiety Disorders [J].
Blessing, Esther M. ;
Steenkamp, Maria M. ;
Manzanares, Jorge ;
Marmar, Charles R. .
NEUROTHERAPEUTICS, 2015, 12 (04) :825-836
[9]   Cannabidiol (CBD) use in psychiatric disorders: A systematic review [J].
Bonaccorso, Stefania ;
Ricciardi, Angelo ;
Zangani, Caroline ;
Chiappini, Stefania ;
Schifano, Fabrizio .
NEUROTOXICOLOGY, 2019, 74 :282-298
[10]   Genetic factors involved in the effects of developmental low-level alcohol induced behavioral alterations in rats [J].
Cagiano, R ;
Cassano, T ;
Coluccia, A ;
Gaetani, S ;
Giustino, A ;
Steardo, L ;
Tattoli, M ;
Trabace, L ;
Cuomo, V .
NEUROPSYCHOPHARMACOLOGY, 2002, 26 (02) :191-203